Faeth TherapeuticsFTH
13F holders, Q1 2026 (March 31)At the end of Q1 2026, 30 institutions reported holding Faeth Therapeutics Inc. (FTH) in their 13F filings, up 20 from Q4 2025. 20 opened new positions and 2 sold out. The largest holders were Vivo Capital, LLC ($22.8M), Cormorant Asset Management, LP ($9.7M) and Millennium Management ($4.6M). 2 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Faeth Therapeutics Inc.
- Filed as
- SENSEI BIOTHERAPEUTICS INC (Q1 2026)
- CUSIP
- 81728A207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 20 | $64.5M |
| Exits | 2 | $3K |
All 13F filers, Q4 2025 → Q1 2026: 2,109,462 shares bought and 15,301 shares sold, net +2,094,161 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 30 holders
| Vivo Capital, LLC | 1.89% | New | 722,020 | $22.8M |
| Cormorant Asset Management, LP | 0.49% | New | 306,222 | $9.7M |
| Millennium Management | 0.00% | New | 146,565 | $4.6M |
| Franklin Resources Inc. | 0.00% | New | 133,506 | $4.2M |
| Stempoint Capital LP | 0.81% | New | 132,873 | $4.2M |
| Caligan Partners LP | 0.28% | New | 126,002 | $4.0M |
| Trails Edge Capital Partners, LP | 0.93% | New | 125,000 | $3.9M |
| Marshall Wace, LLP | 0.00% | New | 65,730 | $2.1M |
| Goldman Sachs Group Inc. | 0.00% | New | 61,568 | $1.9M |
| HRT Financial LP | 0.00% | New | 58,001 | $1.8M |
| Montanova Capital, LLC | 0.03% | New | 34,549 | $1.1M |
| Bank of America Corp. | 0.00% | Add +10692.5% | 33,025 | $1.0M |
| Renaissance Technologies | 0.00% | Add +178.2% | 32,041 | $1.0M |
| Logos Global Management LP | 0.05% | New | 30,000 | $946K |
| Boothbay Fund Management, LLC | 0.02% | New | 26,124 | $823K |
| Brevan Howard Capital Management LP | 0.01% | New | 20,333 | $641K |
| Fred Alger Management, LLC | 0.00% | New | 18,337 | $578K |
| Balyasny Asset Management L.P. | 0.00% | New | 16,205 | $511K |
| Catalio Capital Management, LP | 0.10% | No change | 14,718 | $464K |
| Geode Capital Management, LLC | 0.00% | New | 9,501 | $300K |
| Jane Street Group, LLC | 0.00% | New | 8,872 | $280K |
| Morgan Stanley | 0.00% | Add +87850.0% | 8,795 | $277K |
| Vanguard Capital Management LLC | 0.00% | — | 7,750 | $244K |
| Ikarian Capital, LLC | 0.03% | Reduce -70.3% | 6,351 | $200K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 6,307 | $199K |
| UBS Group AG | 0.00% | New | 4,529 | $143K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,496 | $47K |
| JPMorgan Chase & Co. | 0.00% | No change | 32 | $804 |
| BNP Paribas Financial Markets | 0.00% | No change | 9 | $284 |
| SBI Securities Co., Ltd. | 0.00% | No change | 4 | $126 |
"% of holder's portfolio" is FTH's weight in each manager's 13F, not the share of Faeth Therapeutics Inc. the manager owns.